PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
14.07%
Revenue growth 1.25-1.5x META's 12.29%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.
11.76%
Gross profit growth similar to META's 12.33%. Walter Schloss would assume both firms track common industry trends.
9.33%
EBIT growth similar to META's 10.27%. Walter Schloss might infer both firms share similar operational efficiencies.
9.33%
Operating income growth at 50-75% of META's 16.44%. Martin Whitman would doubt the firm’s ability to compete efficiently.
12.75%
Net income growth 1.25-1.5x META's 10.17%. Bruce Berkowitz would see if strategic cost cutting or product mix explains this difference.
120.93%
EPS growth above 1.5x META's 10.47%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
124.85%
Diluted EPS growth above 1.5x META's 11.04%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.13%
Both firms reduce share counts. Martin Whitman would compare buyback intensity relative to free cash flow generation.
-0.12%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
3.71%
OCF growth at 50-75% of META's 6.39%. Martin Whitman would question if the firm lags in monetizing sales effectively.
-6.02%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
1849.46%
10Y revenue/share CAGR above 1.5x META's 1223.16%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
1849.46%
5Y revenue/share CAGR above 1.5x META's 190.49%. David Dodd would look for consistent product or market expansions fueling outperformance.
311.24%
3Y revenue/share CAGR above 1.5x META's 77.04%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
304.27%
3Y OCF/share CAGR above 1.5x META's 125.05%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
1935.73%
Net income/share CAGR at 50-75% of META's 2770.56%. Martin Whitman might question if the firm’s product or cost base lags behind.
1935.73%
5Y net income/share CAGR above 1.5x META's 304.58%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
419.49%
3Y net income/share CAGR above 1.5x META's 194.47%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
580.79%
3Y equity/share CAGR above 1.5x META's 66.56%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.24%
AR growth well above META's 14.10%. Michael Burry fears inflated revenue or higher default risk in the near future.
-100.00%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
8.55%
Asset growth above 1.5x META's 5.19%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
8.00%
1.25-1.5x META's 5.80%. Bruce Berkowitz sees if the firm's capital management strategies surpass the competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
14.96%
R&D growth drastically higher vs. META's 6.52%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
13.83%
SG&A growth well above META's 12.01%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.